-
公开(公告)号：US20130040929A1
公开(公告)日：2013-02-14
申请号：US13642646
申请日：2011-05-06
申请人： Jeffrey J. Hale , Jinlong Jiang , Dong-Ming Shen , Zhi-Cai Shi , Min Shu , Zhicai Wu , Cangming Yang
发明人： Jeffrey J. Hale , Jinlong Jiang , Dong-Ming Shen , Zhi-Cai Shi , Min Shu , Zhicai Wu , Cangming Yang
IPC分类号： A61K31/506 , C07D401/04 , A61K31/454 , A61K31/4545 , A61P3/00 , C07D413/14 , A61K31/5377 , A61K31/4985 , A61P3/04 , A61P3/10 , C07D401/14 , A61K31/497
CPC分类号： C07D401/04 , C07D401/14
摘要： Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
-
公开(公告)号：US09365539B2
公开(公告)日：2016-06-14
申请号：US13642646
申请日：2011-05-06
申请人： Jeffrey J. Hale , Jinlong Jiang , Dong-Ming Shen , Zhi-Cai Shi , Min Shu , Zhicai Wu , Cangming Yang
发明人： Jeffrey J. Hale , Jinlong Jiang , Dong-Ming Shen , Zhi-Cai Shi , Min Shu , Zhicai Wu , Cangming Yang
IPC分类号： A61K31/397 , C07D401/04 , C07D401/14
CPC分类号： C07D401/04 , C07D401/14
摘要： Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
-
公开(公告)号：US20130059830A1
公开(公告)日：2013-03-07
申请号：US13696831
申请日：2011-05-16
申请人： Fa-Xiang Ding , Jinlong Jiang , Dong-Ming Shen , Zhi-Cai Shi , Min Shu , Cangming Yang
发明人： Fa-Xiang Ding , Jinlong Jiang , Dong-Ming Shen , Zhi-Cai Shi , Min Shu , Cangming Yang
IPC分类号： A61K31/506 , C07D413/14 , A61P3/00 , A61K31/55 , A61P3/04 , A61P3/10 , C07D401/14 , A61K31/5377
CPC分类号： C07D401/14 , C07D413/14
摘要： Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
-
公开(公告)号：US08785634B2
公开(公告)日：2014-07-22
申请号：US13638976
申请日：2011-04-21
申请人： Fa-Xiang Ding , JinLong Jiang , Dong-Ming Shen , Hong Shen , Zhi-Cai Shi
发明人： Fa-Xiang Ding , JinLong Jiang , Dong-Ming Shen , Hong Shen , Zhi-Cai Shi
IPC分类号： C07D401/00
CPC分类号： C07D491/20 , C07D491/10
摘要： Compounds of structural formula (I) are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
摘要翻译： 结构式（I）的化合物是脯氨酰羧肽酶（PrCP）的抑制剂。 本发明的化合物可用于预防和治疗与PrCP的酶活性相关的病症，例如异常代谢，包括肥胖症; 糖尿病; 代谢综合征; 肥胖相关疾病; 和糖尿病相关疾病。
-
公开(公告)号：US20130023515A1
公开(公告)日：2013-01-24
申请号：US13638976
申请日：2011-04-21
申请人： Fa-Xiang Ding , Jinlong Jiang , Dong-Ming Shen , Hong Shen , Zhi-Cai Shi
发明人： Fa-Xiang Ding , Jinlong Jiang , Dong-Ming Shen , Hong Shen , Zhi-Cai Shi
IPC分类号： C07D491/107 , C07D491/20 , A61K31/438 , A61K31/5377 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/4985 , A61K31/44 , A61P3/04 , A61P3/10 , A61P3/00 , A61K31/444
CPC分类号： C07D491/20 , C07D491/10
摘要： Compounds of structural formula (I) are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
摘要翻译： 结构式（I）的化合物是脯氨酰羧肽酶（PrCP）的抑制剂。 本发明的化合物可用于预防和治疗与PrCP的酶活性相关的病症，例如异常代谢，包括肥胖症; 糖尿病; 代谢综合征; 肥胖相关障碍; 和糖尿病相关疾病。
-
公开(公告)号：US08933113B2
公开(公告)日：2015-01-13
申请号：US13979875
申请日：2012-01-19
申请人： Alejandro Crespo , Ping Lan , Rudrajit Mal , Anthony Ogawa , Hong Shen , Peter J. Sinclair , Zhongxiang Sun , Ellen K. Vande Bunte , Zhicai Wu , Kun Liu , Robert J. DeVita , Dong-Ming Shen , Min Shu , John Qiang Tan , Changhe Qi , Yuguang Wang , Richard Beresis
发明人： Alejandro Crespo , Ping Lan , Rudrajit Mal , Anthony Ogawa , Hong Shen , Peter J. Sinclair , Zhongxiang Sun , Ellen K. Vande Bunte , Zhicai Wu , Kun Liu , Robert J. DeVita , Dong-Ming Shen , Min Shu , John Qiang Tan , Changhe Qi , Yuguang Wang , Richard Beresis
IPC分类号： A61K31/416 , C07D231/56 , A61K31/405 , A61K31/404 , C07D403/06 , C07D209/08 , C07D209/10 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K45/06 , C07D413/06
CPC分类号： C07D413/06 , A61K31/404 , A61K31/4045 , A61K31/405 , A61K31/416 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K45/06 , C07D209/08 , C07D209/10 , C07D231/56 , C07D403/04 , C07D403/06 , C07D405/06
摘要： Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too.
摘要翻译： 公开了式（I）化合物及其药学上可接受的盐，其可用于治疗醛固酮介导的疾病。 还公开了制备式（I）化合物，用于治疗和预防上述疾病和用于制备用于此目的的药物的方法和包含式（I）化合物的药物组合物。
-
公开(公告)号：US20130331419A1
公开(公告)日：2013-12-12
申请号：US13979875
申请日：2012-01-19
申请人： Alejandro Crespo , Ping Lan , Rudrajit Mal , Anthony Ogawa , Hong Shen , Peter J. Sinclair , Zhongxiang Sun , Ellen K. Vande Bunte , Zhicai Wu , Kun Liu , Robert J. DeVita , Dong-Ming Shen , Min Shu , John Qiang Tan , Changhe Qi , Yuguang Wang , Richard Beresis
发明人： Alejandro Crespo , Ping Lan , Rudrajit Mal , Anthony Ogawa , Hong Shen , Peter J. Sinclair , Zhongxiang Sun , Ellen K. Vande Bunte , Zhicai Wu , Kun Liu , Robert J. DeVita , Dong-Ming Shen , Min Shu , John Qiang Tan , Changhe Qi , Yuguang Wang , Richard Beresis
IPC分类号： C07D209/08 , A61K45/06 , C07D231/56 , A61K31/416 , A61K31/422 , C07D413/06 , A61K31/4245 , C07D403/06 , A61K31/4196 , A61K31/405 , A61K31/404
CPC分类号： C07D413/06 , A61K31/404 , A61K31/4045 , A61K31/405 , A61K31/416 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K45/06 , C07D209/08 , C07D209/10 , C07D231/56 , C07D403/04 , C07D403/06 , C07D405/06
摘要： Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too.
摘要翻译： 公开了式（I）化合物及其药学上可接受的盐，其可用于治疗醛固酮介导的疾病。 还公开了制备式（I）化合物，用于治疗和预防上述疾病和用于制备用于此目的的药物的方法和包含式（I）化合物的药物组合物。
-
公开(公告)号：US20130143859A1
公开(公告)日：2013-06-06
申请号：US13702622
申请日：2011-06-03
IPC分类号： A61K31/5377 , A61K45/06 , C07D401/14 , A61K31/4545 , C07D401/04 , A61K31/454
CPC分类号： A61K31/5377 , A61K31/454 , A61K31/4545 , A61K45/06 , C07D401/04 , C07D401/14
摘要： Compounds of structural formulas I-1 and I-2 are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
摘要翻译： 结构式I-1和I-2的化合物是脯氨酰羧肽酶（PrCP）的抑制剂。 本发明的化合物可用于预防和治疗与PrCP的酶活性相关的病症，例如异常代谢，包括肥胖症; 糖尿病; 代谢综合征; 肥胖相关疾病; 和糖尿病相关疾病。
-
公开(公告)号：US08569299B2
公开(公告)日：2013-10-29
申请号：US13702622
申请日：2011-06-03
IPC分类号： A61K31/5377 , A61K31/454 , C07D413/14 , C07D401/02 , C07D401/14
CPC分类号： A61K31/5377 , A61K31/454 , A61K31/4545 , A61K45/06 , C07D401/04 , C07D401/14
摘要： Compounds of structural formulas I-1 and I-2 are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
摘要翻译： 结构式I-1和I-2的化合物是脯氨酰羧肽酶（PrCP）的抑制剂。 本发明的化合物可用于预防和治疗与PrCP的酶活性相关的病症，例如异常代谢，包括肥胖症; 糖尿病; 代谢综合征; 肥胖相关疾病; 和糖尿病相关疾病。
-
公开(公告)号：US20190330239A1
公开(公告)日：2019-10-31
申请号：US16461902
申请日：2017-11-13
申请人： Dong-Ming Shen , Thomas H. Graham , Wensheng LIU , Clare TUDGE , Andreas VERRAS , Jinlong JIANG , Merck Sharp & Dohme Corp.
发明人： Dong-Ming Shen , Thomas H. Graham , Wensheng Liu , Clare Tudge , Andreas Verras , Jinlong Jiang
IPC分类号： C07D515/08 , C07D409/12 , C07D401/12 , C07D403/12 , C07D231/56 , C07D405/12 , C07D487/04 , C07D417/12 , C07D413/12 , C07D409/14
摘要： The present invention relates to a compound represented by formula I′: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.038 秒)